The global cardiovascular drugs market is projected to reach USD 63.96 billion by 2026, exhibiting a CAGR of 3.8% during the forecast period. The increasing prevalence of heart stroke and cardiovascular diseases is one of the key reasons for the growth of the cardiovascular drugs market. According to the American Heart Association, Cardiovascular disease (CVD) accounted for 840,678 deaths in the US in 2016, approximately 1 of every 3 deaths.
Also, between 2013 and 2016, 121.5 million American adults had some form of cardiovascular disease. These cardiovascular drugs market trends, along with the innovation and development of new drugs, will foster the growth of the market. Moreover, In 2014, a study was conducted by the American Heart Association, cardiovascular disease accounted for more than 17.6 million deaths per year in 2016 and is likely to grow to more than 23.6 million by 2030.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/cardiovascular-therapeutics-market-100379
Leading Players operating in the Cardiovascular Drugs Market are:
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- AstraZeneca
- Sanofi
- Novartis AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche Ltd
New Product Launches Will Propel Growth
India based Natco Pharma announced the launch of the generic version of valsartan-sacubitril, a cardiovascular drug for the treatment of congestive heart failure. Novartis AG holds the patent in India for valsartan-sacubitril called Vymada. The launch of the new drug will create growth opportunities for the market in the foreseeable future. Furthermore, increasing awareness regarding cardiovascular health and the surge in product launches will boost cardiovascular drugs market growth.
The introduction of several advanced drugs addressing the diverse treatment needs of cardiovascular diseases will further bolster the growth of the market. For instance, Bristol-Myers Squibb Company and Pfizer Inc. introduced a cardiovascular drug called Eliquis (apixaban), which now has the highest sales and is demonstrated to be superior in terms of risk reductions compared to other drugs in the market.
Request a Sample Copy of the Cardiovascular Drugs Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiovascular-therapeutics-market-100379
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Major Cardiovascular Diseases by Key Countries
- Pipeline Analysis
- Key Industry Developments Such as Mergers & Acquisitions
- New Product Launches
- The Regulatory Scenario in Key Countries
- Reimbursement Scenario by Key Countries
- Advances in R&D for Novel Therapeutics
- Global Cardiovascular Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Type
- Antihypertensive
- Antihyperlipidemic
- Anticoagulants
- Antiplatelet Drugs
- Others
- Market Analysis, Insights and Forecast – By Disease Indication
- Hypertension
- Hyperlipidemia
- Coronary Artery Disease
- Arrhythmia
- Others
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Cardiovascular Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis – By Drug Type
- Antihypertensive
- Antihyperlipidemic
- Anticoagulants
- Antiplatelet Drugs
- Others
- Market Analysis – By Disease Indication
- Hypertension
- Hyperlipidemia
- Coronary Artery Disease
- Arrhythmia
- Others
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis – By Country
- U.S.
- Canada
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/cardiovascular-therapeutics-market-100379
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
